annb0t
Top 20
Study conducted by Meiji Seika Pharma in Japan
Data follow approval of the worldâs first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine for Adults by Japan Ministry of Health, Labor and Welfare The randomized, double-blind, active-controlled study, conducted at 11 sites in Japan, was designed to compare the immunogenicity and tolerability of the sa-mRNA vaccine ARCT-154 with Comirnaty® Phase 3 Study published in The Lancet Infectious Diseases
KING OF PRUSSIA, Pa. & SAN DIEGO,...
>>> Read more: CSL and Arcturus Therapeuticsâ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Data follow approval of the worldâs first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine for Adults by Japan Ministry of Health, Labor and Welfare The randomized, double-blind, active-controlled study, conducted at 11 sites in Japan, was designed to compare the immunogenicity and tolerability of the sa-mRNA vaccine ARCT-154 with Comirnaty® Phase 3 Study published in The Lancet Infectious Diseases
KING OF PRUSSIA, Pa. & SAN DIEGO,...
>>> Read more: CSL and Arcturus Therapeuticsâ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
